These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 15373046)
41. Analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and quality of life at 24 weeks. Sayana S; Prosser P; Ricaurte JC; Sanchez S; Hamwi G; Hershey-Weber J; Chien C; Easley A; Nguyen T; Wilson L; Khanlou H J Int Assoc Physicians AIDS Care (Chic); 2009; 8(2):85-6. PubMed ID: 19369697 [No Abstract] [Full Text] [Related]
42. Virologic and immunologic impact and durability of enfuvirtide-based antiretroviral therapy in HIV-infected treatment-experienced patients in a clinical setting. Loutfy MR; Antoniou T; Shen S; Diong C; Vlaicu M; Halpenny R; Kovacs C; Fletcher D; Raboud JM HIV Clin Trials; 2007; 8(1):36-44. PubMed ID: 17434847 [TBL] [Abstract][Full Text] [Related]
44. A cohort study of enfuvirtide immunological and virological efficacy in clinical practice. Bienvenu B; Krivine A; Rollot F; Pietri MP; Lebault V; Meritet JF; Guerin C; Spiridon G; Salmon D; Guillevin L; Lebon P; Launay O J Med Virol; 2006 Oct; 78(10):1312-7. PubMed ID: 16927284 [TBL] [Abstract][Full Text] [Related]
45. Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy. Melby TE; Despirito M; Demasi RA; Heilek G; Thommes JA; Greenberg ML; Graham N AIDS; 2007 Nov; 21(18):2537-9. PubMed ID: 18025893 [TBL] [Abstract][Full Text] [Related]
46. [First fusion inhibitor is available. No entry for HIV-1 viruses]. MMW Fortschr Med; 2003 Jun; 145(25):51. PubMed ID: 12891854 [No Abstract] [Full Text] [Related]
47. Selective increase in serum IgE following enfuvirtide administration in HIV-1 infected multidrug resistant patients. Hasson H; Biswas P; Galli L; Burastero SE; Danise A; Bigoloni A; Carini E; Locatelli M; Vecchi A; Lazzarin A; Castagna A New Microbiol; 2006 Oct; 29(4):223-30. PubMed ID: 17201088 [TBL] [Abstract][Full Text] [Related]
48. Enfuvirtide, a new drug for HIV infection. Fletcher CV Lancet; 2003 May; 361(9369):1577-8. PubMed ID: 12747873 [No Abstract] [Full Text] [Related]
49. FDA notifications. FDA approves Fuzeon, the first fusion inhibitor. AIDS Alert; 2003 Jun; 18(6):78-9. PubMed ID: 12866478 [No Abstract] [Full Text] [Related]
50. [Enfuvirtide, mechanism of action and pharmacological properties]. Kapić E; Becić F; Zvizdić S Med Arh; 2005; 59(5):313-6. PubMed ID: 16134757 [TBL] [Abstract][Full Text] [Related]
51. T-20 continues to look promising. AIDS Patient Care STDS; 1999 Dec; 13(12):753. PubMed ID: 10743540 [No Abstract] [Full Text] [Related]
52. [Clinical efficacy and tolerance of enfuvirtide (Fuzeon), new antiretroviral inhibitors of intracellular penetration of human immunodeficiency virus (HIV) type 1]. Raffi F Med Mal Infect; 2004 Sep; 34 Spec No 1():8-17. PubMed ID: 15742550 [TBL] [Abstract][Full Text] [Related]
53. Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients. Salzberger B; Däumer M; Gute P; Jaeger H; Knechten H; van Lunzen J; Mauss S; Mayr C; Moll A; Plettenberg A; Rockstroh J; Staszewski S; Stellbrink HJ; Stoll M; Sturmer M Eur J Med Res; 2007 Mar; 12(3):93-102. PubMed ID: 17507306 [TBL] [Abstract][Full Text] [Related]
54. HIV entry inhibitors: progress in development and application. Lai WH; Huang L; Chen CH Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414 [TBL] [Abstract][Full Text] [Related]